Alvotech, Teva Reports FDA Approval For SELARSDI (Ustekinumab-aekn) In New Presentation, 130 Mg/26 Ml (5 Mg/Ml) Solution In Single-dose Vial For Intravenous Infusion
Portfolio Pulse from Benzinga Newsdesk
Alvotech and Teva have received FDA approval for SELARSDI, a biosimilar to Stelara, in a new presentation. The product is expected to launch in Q1 2025.
October 22, 2024 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alvotech has received FDA approval for SELARSDI, a biosimilar to Stelara, which is expected to launch in Q1 2025. This approval could enhance Alvotech's market position in the biosimilar space.
The FDA approval of SELARSDI is a significant milestone for Alvotech, potentially increasing its market share in the biosimilar industry. The alignment with Stelara's indications suggests a strong market potential.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Teva, in collaboration with Alvotech, has received FDA approval for SELARSDI, a biosimilar to Stelara. The product is set to launch in Q1 2025, potentially strengthening Teva's biosimilar portfolio.
Teva's involvement in the FDA-approved SELARSDI could bolster its biosimilar portfolio, offering a competitive edge in the market. The upcoming launch aligns with strategic growth in biosimilars.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70